PLGA-mPEG, MW x 16K, n 5K provides a biodegradable amphiphilic block copolymer for nanoparticle formulation and controlled drug delivery research and specifically combines a 16 kDa poly(lactic-co-glycolic acid) (PLGA) block with a 5 kDa methoxy polyethylene glycol (mPEG) chain. Its amphiphilic composition supports hydrophobic drug encapsulation, while the PEG segment contributes surface hydration and colloidal stability under suitable formulation conditions.
Key Features and Benefits
- 16 kDa PLGA Block: Provides a biodegradable hydrophobic polyester segment for polymeric nanoparticle formation, drug encapsulation, and sustained-release formulation research.
- 5 kDa mPEG Block: Introduces a hydrophilic PEG chain that specifically contributes to nanoparticle surface hydration and aqueous dispersion properties.
- Amphiphilic Structure: Combines hydrophobic PLGA and hydrophilic mPEG segments to specifically support nanoparticle formation under suitable processing conditions.
- Biodegradable Backbone: Contains hydrolytically degradable ester bonds that specifically enable investigations of polymer degradation, matrix erosion, and drug release behavior.
- Defined Block Composition: Features a nominal 3.2:1 PLGA-to-mPEG molecular weight ratio, combining a substantial hydrophobic fraction with hydrophilic functionality.
- Methoxy-Terminated PEG: Incorporates a methyl ether terminus without a dedicated reactive conjugation group, supporting preparation of PEG-containing polymeric materials.
- Hydrophilic Surface Functionality: Provides PEG chains that may influence nanoparticle hydration, protein interactions, aggregation, and dispersion stability.
- Controlled-Release Potential: Supports biodegradable polymer matrices for evaluating drug diffusion, polymer hydrolysis, and sustained-release behavior.
- Formulation Versatility: Accommodates nanoprecipitation, emulsification, and solvent evaporation methods for developing polymeric nanoparticles with different characteristics.
Applications
- Polymeric Nanoparticle Development: Supports preparation of biodegradable nanoparticles containing PLGA-rich hydrophobic domains and hydrophilic mPEG segments.
- Hydrophobic Drug Encapsulation: Enables incorporation of compatible, poorly water-soluble compounds into biodegradable PLGA-based polymer matrices.
- Controlled Drug Release: Supports investigations of drug diffusion, polymer degradation, and matrix erosion in sustained-release formulations.
- Drug Delivery Research: Facilitates development of biodegradable polymer carriers for encapsulating and delivering compatible therapeutic research compounds.
- Nanoparticle Surface Engineering: Enables evaluation of PEG chain effects on particle hydration, surface interactions, aggregation, and colloidal stability.
- Polymer Degradation Studies: Supports characterization of PLGA hydrolysis, molecular weight reduction, and degradation-dependent drug release behavior.
- Biodegradable Biomaterials: Provides a polymer building block for developing experimental biodegradable materials and evaluating their structural and degradation properties.
- Nanoparticle Stability Studies: Facilitates analysis of particle size, size distribution, aggregation, and dispersion stability under different formulation conditions.
- Polymer Composition Research: Supports comparisons of PLGA-to-PEG ratios and their effects on nanoparticle formation, drug loading, and release profiles.
Storage and Handling
- Storage: Store at −20°C in a dry, tightly sealed container, protected from moisture and excessive heat. Follow product-specific storage instructions when available, and minimize humidity exposure to reduce premature PLGA hydrolysis.
- Handling: Handle using clean, dry equipment and dissolve in a compatible solvent, such as dichloromethane, acetone, DMF, or DMSO. Confirm solubility before selecting the formulation method.
- Prepare nanoparticles through nanoprecipitation, emulsification, or solvent evaporation, depending on the desired formulation characteristics. The nominal 3.2:1 PLGA-to-mPEG ratio provides a substantial hydrophobic fraction with approximately 23.8% PEG by nominal block mass.
- Evaluate particle size, stability, drug loading, and release behavior using suitable analytical techniques. Avoid prolonged exposure to moisture, strong acids, and alkaline conditions. Confirm the PLGA lactide-to-glycolide ratio and polymer specifications before use.
PLGA-mPEG, MW x 16K, n 5K combines biodegradable PLGA with hydrophilic mPEG for polymeric nanoparticle and biomaterials research and specifically supports hydrophobic drug encapsulation, controlled-release development, polymer degradation studies, and nanoparticle characterization.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.